RNAi treatment controls blood pressure in key trial

“RNA interference (RNAi) is the process of mRNA degradation, which is very specific. There are only a few such drugs approved yet. Zilebesiran [from Roche and Almylan] targets liver-expressed angiotensinogen (AGT), which is the sole precursor of angiotensin peptides. AGT is the most upstream precursor in the Renin-Angiotensin-Aldosterone System, a cascade that has a key role in blood pressure regulation and AGT’s inhibition has well-established antihypertensive effects.”        MORE

Image Credit:  InsidePresicionMedicine